Search Results - "MUUS, P."

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome by Legendre, C.M, Licht, C, Muus, P, Greenbaum, L.A, Babu, S, Bedrosian, C, Bingham, C, Cohen, D.J, Delmas, Y, Douglas, K, Eitner, F, Feldkamp, T, Fouque, D, Furman, R.R, Gaber, O, Herthelius, M, Hourmant, M, Karpman, D, Lebranchu, Y, Mariat, C, Menne, J, Moulin, B, Nürnberger, J, Ogawa, M, Remuzzi, G, Richard, T, Sberro-Soussan, R, Severino, B, Sheerin, N.S, Trivelli, A, Zimmerhackl, L.B, Goodship, T, Loirat, C

“…This article describes the use of eculizumab in patients with atypical hemolytic–uremic syndrome. This C5 inhibitor was associated with improvement in…”
Get full text

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry by Schrezenmeier, Hubert, Muus, Petra, Socié, Gérard, Szer, Jeffrey, Urbano-Ispizua, Alvaro, Maciejewski, Jaroslaw P, Brodsky, Robert A, Bessler, Monica, Kanakura, Yuzuru, Rosse, Wendell, Khursigara, Gus, Bedrosian, Camille, Hillmen, Peter

“…Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease associated with hemolytic anemia, bone marrow failure, thrombosis, and, frequently, poor…”
Get full text

Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry by Socié, G., Schrezenmeier, H., Muus, P., Lisukov, I., Röth, A., Kulasekararaj, A., Lee, J. W., Araten, D., Hill, A., Brodsky, R., Urbano-Ispizua, A., Szer, J., Wilson, A., Hillmen, P.

“…Background Paroxysmal nocturnal haemoglobinuria (PNH) is a rare disease. Although much progress has been made in the understanding of the pathophysiology of…”
Get full text

Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria by VAN BIJNEN, S. T. A., VAN HEERDE, W. L., MUUS, P.

“…Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disease characterized by a clone of blood cells lacking glycosyl phosphatidylinositol…”
Get full text

Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab by Bijnen, S. T. A., Wouters, D., Mierlo, G. J., Muus, P., Zeerleder, S.

“…Summary Background Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement‐mediated hemolysis and a high risk of life‐threatening venous and…”
Get full text

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) by Saft, Leonie, Karimi, Mohsen, Ghaderi, Mehran, Matolcsy, András, Mufti, Ghulam J, Kulasekararaj, Austin, Göhring, Gudrun, Giagounidis, Aristoteles, Selleslag, Dominik, Muus, Petra, Sanz, Guillermo, Mittelman, Moshe, Bowen, David, Porwit, Anna, Fu, Tommy, Backstrom, Jay, Fenaux, Pierre, MacBeth, Kyle J, Hellström-Lindberg, Eva

“…Del(5q) myelodysplastic syndromes defined by the International Prognostic Scoring System as low- or intermediate-1-risk (lower-risk) are considered to have an…”
Get full text

Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40 by Rijneveld, A W, van der Holt, B, Daenen, S M G J, Biemond, B J, de Weerdt, O, Muus, P, Maertens, J, Mattijssen, V, Demuynck, H, Legdeur, M C J C, Wijermans, P W, Wittebol, S, Spoelstra, F M, Dekker, A W, Ossenkoppele, G J, Willemze, R, Cornelissen, J J

“…Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is >80%. Outcome in adult ALL is still unsatisfactory, which is due to…”
Get full text

Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab by van Bijnen, S.T.A, Østerud, B, Barteling, W, Verbeek-Knobbe, K, Willemsen, M, van Heerde, W.L, Muus, P

“…Abstract Background Paroxysmal Nocturnal Hemoglobinuria is characterized by complement-mediated hemolysis and an increased thrombosis risk. Eculizumab, an…”
Get full text

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial by DE WITTE, Theo, HAGEMEIJER, Anne, AMADORI, Sergio, MUUS, Petra, JANSEN, Joop H, HELLSTRÖM-LINDBERG, Eva, KOVACSOVICS, Tibor, WIJERMANS, Pierre, OSSENKOPPELE, Gert, GRATWOHL, Alois, MARIE, Jean-Pierre, WILLEMZE, Roel, SUCIU, Stefan, BELHABRI, Amin, DELFORGE, Michel, KOBBE, Guido, SELLESLAG, Dominik, SCHOUTEN, Harry C, FERRANT, Augustin, BIERSACK, Harald

“…Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic…”
Get full text

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT by Hengeveld, M, Suciu, S, Chelgoum, Y, Marie, J-P, Muus, P, Lefrère, F, Mandelli, F, Pane, F, Amadori, S, Fioritoni, G, Labar, B, Baron, F, Cermak, J, Bourhis, J-H, Storti, G, Fazi, P, Hagemeijer, A, Vignetti, M, Willemze, R, de Witte, T

“…The faster hematopoietic recovery after autologous peripheral blood SCT (APBSCT) in patients with AML may be offset by an increased relapse risk as compared…”
Get full text

97 CHARACTERISTICS OF ROMIPLOSTIM-TREATED MDS PATIENTS WITH HEMATOLOGIC IMPROVEMENT IN PLATELETS (HI-P) by Fenaux, P, Muus, P, Kantarjian, H, Lyons, R.M, Larson, R.A, Sekeres, M.A, Becker, P.S, Orejudos, A, Franklin, J

Get full text

Rapidly evolving skin manifestations due to progressive thrombosis in a patient with paroxysmal nocturnal haemoglobinuria resolved with prompt initiation of eculizumab by Otters, E.F.M., Zarafonitis, G., Steenbergen, E.J., van der Valk, P.G.M., Muus, P.

Get full text

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial) by Willemze, R., Suciu, S., Muus, P., Halkes, C. J. M., Meloni, G., Meert, L., Karrasch, M., Rapion, J., Vignetti, M., Amadori, S., de Witte, T., Marie, J. P.

“…This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine…”
Get full text

Gemtuzumab ozogamicin (Mylotarg ) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups by AMADORI, S, SUCIU, S, PRUIJT, J, NOBILE, F, CASSIBBA, V, MARIE, J.-P, BEELDENS, F, BAILA, L, VIGNETTI, M, DE WITTE, T, STASI, R, WILLEMZE, R, MANDELLI, F, SELLESLAG, D, DENZLINGER, C, MUUS, P, STAUDER, R, BERNEMAN, Z

“…The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40 patients >60 years of age with acute myeloid leukemia (AML) who were…”
Get full text

Need for early recognition and therapeutic guidelines of congenital sideroblastic anaemia by Cuijpers, M. L. H., van Spronsen, D. J., Muus, P., Hamel, B. C. J., Swinkels, D. W.

“…We present a patient with iron overload, who was initially diagnosed with hereditary haemochromatosis. Family analysis, however, established that the iron…”
Get full text

Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON by Daenen, S, van der Holt, B, Dekker, A W, Willemze, R, Rijneveld, A W, Biemond, B J, Muus, P, van de Loosdrecht, A A, Schouten, H C, van Marwijk Kooy, M, Breems, D A, Demuynck, H, Maertens, J, Wijermans, P W, Wittebol, S, de Klerk, E W, Cornelissen, J J

Get full text

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia by FENAUX, P, CHEVRET, S, BORDESSOULE, D, STOPPA, A.-M, SACLOUN, A, MUUS, P, WANDT, H, MINEUR, P, WHITTAKER, J, FEY, M, DANIEL, M.-T, CASTAIGNE, S, GUERCI, A, DEGOS, L, FEGUEUX, N, DOMBRET, H, THOMAS, X, SANZ, M, LINK, H, MALOISEL, F, GARDIN, C

“…First results of a randomized trial (APL91 trial) and other randomized or non-randomized studies have shown that ATRA followed by chemotherapy significantly…”
Get full text

P-180 Final report of an open-label extension (OLE) study of romiplostim in MDS with a focus on patients with prolonged treatment by Fenaux, P, Kantarjian, H, Muus, P, Lyons, R.M, Larson, R.A, Sekeres, M.A, Becker, P.S, Jia, C, Yang, A.S

Get full text

62 MUTATIONS IN EPIGENETIC REGULATORS ARE SIGNIFICANTLY ASSOCIATED WITH ABERRANT EXPRESSION OF MYELOID DIFFERENTIATION ANTIGENS ON MYELOID PROGENITOR CELLS IN LOW/INTERMEDIATE RISK MDS by Coelho, P. Silva, Cremers, E.M.P, Westers, T.M, de Graaf, A.O, Alhan, C, Cali, C, Visser-Wisselaar, H.A, Chitu, D.A, Vellenga, E, Klein, S.K, Wijermans, P.W, de Greef, G.E, Legdeur, M.C, Muus, P, Ossenkoppele, G.J, Stevens-Kroef, M.J.P.L, van der Reijden, B, Jansen, J.H, van de Loosdrecht, A.A

Get full text

P-277 Decitabine vs. best supportive care in elderly higher-risk MDS patients with or without monosomal karyotypes: EORTC-LG/GMDS-SG phase III trial 06011 by Lübbert, M, Suciu, S, Hagemeijer, A, Platzbecker, U, Giagounidis, A, Selleslag, D, Germing, U, Salih, H.R, Muus, P, Bogatyreva, L, Aul, C, De Witte, T, Ganser, A, Huls, G, Marie, J.P, Wijermans, P

Get full text